Safety and Immunogenicity of AdCh63 ME-TRAP and MVA ME-TRAP Vaccines in Malaria Endemic Areas

Inclusion Criteria:

• Consenting adult males aged 18-50 years in good health.
• Will remain resident in the study area for the study duration

Exclusion Criteria:

• Clinically significant history of the following conditions; skin disorder (eczema, etc.), allergy, symptomatic immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness.
• History of splenectomy
• Haemoglobin less than 9.0 g/dl
• Clinically significant abnormalities of laboratory screening tests (full blood count, ALT, creatinine levels, urine dipstick examination for blood and protein).
• Blood transfusion within one month of the beginning of the study
• History of vaccination with previous experimental malaria vaccines
• Administration of any other vaccine or immunoglobulin within two weeks before vaccination.
• Current participation in another clinical trial, or within 12 weeks of this study
• Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial.
• Likelihood of travel away from the study area
• HIV positive.
• History of contact dermatitis (due to the use of a potentially irritant disinfectant that may be present in trace amounts in the AdCh63 ME-TRAP vaccine, see the investigators brochure for details, attached)